Remepy, a New York-based hybrid drugs developer, closed a $10M seed funding round, which, together with earlier funding, totalled $15M.
The round was led by NFX, joined by Vine Ventures, PsyMed Ventures, Supernode Ventures and Firstime Ventures, joining previous pre-seed lead investor TechAviv as well as Fresh.fund, Samsung Next, StageNext Fund and 97212 Ventures.
Led by Dr. Michal Tsur, and Or Shoval, Remepy is pioneering Hybrid Drugs, which are traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments. Digital molecules are therapeutic interventions that trigger physiological effects (aka MOAs, Mechanisms of Action) through the brain. These physiological changes have been known to enhance the effectiveness of traditional drugs.
The company has already proven in human studies the effect of its products, using extensive brain imaging, as well as blood and saliva samples, with promising results for Oncology, MCI, and Parkinson’s Disease.
Remepy is targeting neurodegenerative diseases, cancer, autoimmune diseases, and degenerative eye diseases.
FinSMEs
01/05/2024